COMBINATION METFORMIN AND ORAL CONTRACEPTIVE FOR PCOS

二甲双胍和口服避孕药复方治疗多囊卵巢综合征

• 批准号: 8166540
• 负责人: PAULINA A ESSAH
• 金额: $ 0.21万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166540
• 关键词: Cardiovascular Diseases; Computer Retrieval of Information on Scientific Projects Database; Fertility; Funding; Grant; Institution; Insulin; Insulin Resistance; Maintenance Therapy; Metformin; Oral Contraceptives; Research; Research Personnel; Resources; Risk Factors; Source; United States National Institutes of Health; Woman; insulin sensitizing drugs; pill

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The central hypothesis underlying this study is that a combination of insulin-sensitization to an oral contraceptive pill (OCP) is the optimal maintenance therapy for women with PCOS not desiring fertility because it combines the beneficial effects of both agents, and through the actions of the insulin-sensitizer, reduces insulin resistance and risk factors for cardiovascular disease.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的中心假设是，口服避孕药(OCP)的胰岛素增敏组合是不希望生育的PCOS女性的最佳维持疗法，因为它结合了两种药物的有益效果，并通过胰岛素增敏剂的作用，降低了胰岛素抵抗和心血管疾病的风险因素。